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Microvesicles (MVs) play an important role in intercel-
lular  communication  by  carrying  mRNAs,  microRNAs 
(miRNAs), non-coding RNAs, proteins, and DNA from 
cell  to  cell.  To  our  knowledge,  this  is  the  first  report 
of delivery of a therapeutic mRNA/protein via MVs for 
treatment of cancer. We first generated genetically engi-
neered MVs by expressing high levels of the suicide gene 
mRNA and protein–cytosine deaminase (CD) fused to 
uracil  phosphoribosyltransferase  (UPRT)  in  MV  donor 
cells. MVs were isolated from these cells and used to treat 
pre-established  nerve  sheath  tumors    (schwannomas) 
in an orthotopic mouse model. We demonstrated that 
MV-mediated  delivery  of  CD-UPRT  mRNA/protein  by 
direct injection into schwannomas led to regression of 
these tumors upon systemic treatment with the prod-
rug (5-fluorocytosine (5-FC)), which is converted within 
tumor cells to 5-fluorouracil (5-FU)–an anticancer agent. 
Taken together, these studies suggest that MVs can serve 
as novel cell-derived “liposomes” to effectively deliver 
therapeutic mRNA/proteins to treatment of diseases.
Received 21 January 2012; accepted 16 July 2012; advance online 
publication 21 August 2012. doi:10.1038/mt.2012.161
IntroductIon
Cancer  therapeutic  strategies  include  gene  delivery  to  target 
cancer cells in order to replace dysfunctional tumor suppressor 
genes, elicit immune rejection or drive tumor cells into apoptotic 
pathways.  To  date,  several  biological  delivery  vehicles,  includ-
ing DNA, cationic liposomes, viral vectors, and small-interfering 
RNA (siRNA) nanoparticles have been used with advantages and 
limitations.1,2 Naked genetic materials are inefficient in targeting 
because of rapid clearance by extracellular nucleases.3 Liposomes 
can efficiently load genetic molecules, however, their clearance 
rate and immunogenicity put limitations on clinical applications.4 
Many viral gene delivery vehicles, such as herpes simplex virus, 
adenovirus,  adeno-associated  virus,  and  retrovirus/lentivirus 
vectors can efficiently transfer genetic material inside tumor cells, 
however, with limitations in some cases, such as small packaging 
capacity, loss with cell division, immune response to viral parti-
cles, and insertional mutagenesis.5–7 Virus and liposome delivery 
tools are recognized by the host immune system as foreign parti-
cles resulting in generation of antibodies against them and thereby 
decreasing transgene delivery dramatically upon repeated admin-
istration, as well as causing immune rejection of transduced cells.8 
Lipid nanoparticles are susceptible to opsonin and complement 
system-mediated clearance in the blood and following uptake into 
endosomes can trigger the activation of TLR7/8 resulting in trans-
gene silencing.9 Polymeric siRNA nanoparticles such as polyethyl-
enimine-siRNA can be subjected to rapid clearance upon binding 
to serum proteins. Although polymeric nanoparticles can escape 
from endosomes through the proton sponge effect of polyethyl-
enimine and effectively deliver siRNA to the cytosol, leakage of 
endosomal and lysosomal membrane components can result in 
release of cathepsin B and inflammasome activation.10 In addi-
tion, polyethylenimine complexes, as well as virus vectors, tend 
to accumulate in lung, liver, and spleen, which make targeting to 
other tissues and tumors challenging.11
Microvesicles (MVs), on the contrary, are a natural mamma-
lian delivery system used by many cell types under both normal 
physiological and pathological conditions.12 They include a variety 
of different vesicle types, variously termed exosomes, shed MVs 
and microparticles, ranging in size from 50 to 800 nm in diam-
eter. They are released into the extracellular environment through 
fusion of endosome-derived multivesicular bodies with the plasma 
membrane and by budding from the plasma membrane.12–17 These 
small vesicles are released by cancer cells in abundance as a means 
to modify the tumor microenvironment.18–23 Recent studies have 
shown that MVs can function to carry a multitude of cargos, 
including  mRNAs,  proteins,  microRNA  (miRNA),  non-coding 
RNAs, and DNA between cells.22–27
Based on the capacity of MVs to transfer cargo, in the present 
study, we evaluated whether MVs can serve as a novel cell-derived 
gene delivery vehicle carrying therapeutic mRNA/protein for cancer 
The first two authors equally contributed to this study.
Correspondence: Okay Saydam, Molecular Neuro-Oncology Research Unit, Department of Pediatrics, Medical University of Vienna, Vienna 1090, 
Austria. E-mail: okay.saydam@meduniwien.ac.at
Genetically Engineered Microvesicles Carrying 
Suicide mRNA/Protein Inhibit Schwannoma 
Tumor Growth
Arda Mizrak1,2, Mehmet Fatih Bolukbasi1,2, Gokhan Baris Ozdener1,2, Gary J Brenner3, Sibylle Madlener4, 
Erdogan Pekcan Erkan4, Thomas Ströbel5, Xandra O Breakefield1,2 and Okay Saydam4
1Department of Neurology and Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA; 2Program in Neuroscience, Harvard Medical 
School, Boston, Massachusetts, USA; 3Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, 
Massachusetts, USA; 4Molecular Neuro-Oncology Research Unit, Department of Pediatrics, Medical University of Vienna, Vienna, Austria; 5Institute of 
Neurology, Medical University of Vienna, Vienna, Austria
MTOpen102  www.moleculartherapy.org  vol. 21 no. 1 jan. 2013
© The American Society of Gene & Cell Therapy
Microvesicles as Cancer Treatment Tool
treatment.  To  test  this  hypothesis,  we  generated  cells  which  sta-
bly expressed the suicide therapeutic mRNA/protein for cytosine 
deaminase (CD) fused in-frame with uracil phosphoribosyltrans-
ferase (UPRT), previously shown to be a potent prodrug-activating 
combination.28 MVs were harvested from these cells and used to 
treat schwannoma tumors. CD converts 5-fluorocytosine (5-FC) to 
5-fluorouracil (5-FU), which is especially toxic to cells expressing 
UPRT due to its conversion to 5-fluoro-deoxyuridine monophos-
phate (5-FdUMP), an irreversible inhibitor of thymidine synthetase, 
thereby restricting the production of dTMP and downstream phos-
phorylated products. Depletion of dTTP results in inhibition of DNA 
synthesis and causes cells to go under apoptosis.29,30 We showed that 
with overexpression of the suicide gene in donor cells, high amounts 
of CD-UPRT message and protein were incorporated into MVs. 
These MVs were capable of transferring this therapeutic mRNA/
protein to target tumor cells thereby achieving high level expression 
of functional protein in these recipient cells. Two different in vivo 
experiments resulted in significant inhibition of schwannoma tumor 
growth when CD-UPRT carrying MVs were injected into tumors in 
combination with systemic delivery of the prodrug, 5-FC.
results
use of genetically engineered MVs as a novel gene 
delivery tool
The general plan of action was to transduce donor cells with an 
expression cassette for a therapeutic gene, in this case CD-UPRT-
EGFP (enhanced green fluorescent protein) under a strong pro-
moter (the cytomegalovirus promoter) and to allow time for high 
level expression of the cassette (72 hours). Then MVs were iso-
lated from the conditioned medium by differential centrifugation, 
ultracentrifugation, and filtration. These MVs were evaluated for 
enrichment of CD-UPRT-EGFP mRNA and protein (see below) 
and injected into tumors, followed, in this case, by systemic prod-
rug  administration  (5-FC)  which  should  trigger  apoptosis  of 
tumor cells and regression of tumors. A schematic overview of the 
experiments performed in this study is illustrated in Figure 1.
cd-uPrt-eGFP mrnA and protein are enriched in 
MVs
To test whether the CD-UPRT-EGFP mRNAs are enriched in 
MVs,  we  first  transfected  HEK-293T  either  with  pCD-UPRT-
EGFP or pEGFP, and 3 days after transfection MVs were collected 
from medium and treated with DNaseI to remove any residual 
plasmid DNA bound to the surface of the MVs. Then RNA was 
isolated from MVs and quantitative reverse transcription-PCRs 
(RT-PCRs)  were  performed  for  CD-UPRT-EGFP  and  glycer-
aldehyde  3-phosphate  dehydrogenase  (GAPDH)  mRNAs  and 
end PCR products were loaded onto agarose gel. As shown in 
Figure 2a, we detected the CD-UPRT-EGFP mRNA only in MVs 
isolated from pCD-UPRT-EGFP–transfected cells, compared with 
control pEGFP or non-transfected cells (Figure 2a). Moreover, to 
investigate the origin of the quantitative RT-PCR signal, we per-
formed the following treatments: with and without DNaseI on 
intact MVs and after release of MV contents, and RNase treatment 
after RNA isolation from MVs. As shown in Figure 2b, DNaseI 
treatment on the outside of MVs did not prevent amplification 
CMV
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Figure 1  engineering MVs as novel gene delivery tools. The therapeutic expression vector, in this case CD-UPRT-EGFP is delivered into donor 
cells via DNA transfection or infection with a viral vector. A few days later, MVs enriched with expressed mRNAs/protein are harvested from the con-
ditioned medium and concentrated by ultracentrifugation. Recipient cancer cells/tumor are treated with those MVs followed a few days later by an 
administration of an activating agent, in this case the prodrug, 5-FC. CD and UPRT converts 5-FC to 5-FdUMP, an irreversible inhibitor of thymidine 
synthetase, thereby restricting the production of dTMP. Depletion of dTTP results in inhibition of DNA synthesis and leads to apoptosis of cancer cells. 
5-FC, 5-fluorocytosine; 5-FdUMP, 5-fluoro-deoxyuridine monophosphate; CD, cytosine deaminase; CMV, cytomegalovirus; EGFP, enhanced green 
fluorescent protein; MV, microvesicle; UPRT, uracil phosphoribosyltransferase.Molecular Therapy  vol. 21 no. 1 jan. 2013  103
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of the RT-PCR product, whereas after RNase treatment of the 
contents of MVs, no signal was observed (Figure 2b). In order to 
determine whether DNaseI treatment of MVs was functional, we 
also performed quantitative PCR (qPCR) directly (without RT) 
on the contents of isolated MVs and found no PCR product, sup-
porting the conclusion that the PCR amplicons observed in our 
experimental conditions came entirely from mRNAs within MVs 
and not from any plasmid DNA contamination during MVs isola-
tion (Figure 2c). Since MVs can carry proteins as well as RNAs, 
we next determined whether CD-UPRT-EGFP protein was also 
incorporated  into  MVs.  We  performed  western  blots  directly 
on isolated MVs lysates using anti-CD antibody and found that 
MVs  from  CD-UPRT-EGFP–transfected  cells  also  contained 
CD-UPRT-EGFP protein (Figure 2d).
We next examined whether MVs could mediate mRNA/protein 
delivery into recipient cells in culture. We employed HEI-193 cells, 
human NF2 schwannoma cells immortalized with an oncogene31 
as recipient tumor cells based on our recently developed orthoto-
pic  schwannoma  mouse  model.32,33  Donor  HEK-293T  cells  (4  × 
107) were transfected with pCD-UPRT-EGFP and 3 days later MVs 
were collected and concentrated as above in a 50 µl volume. HEI-193 
cells (105) were treated for 2 days with increasing volumes of MV 
concentrate–1, 3, and 5 µl corresponding to MVs released from 8 × 
105 (1 µl), 2.4 × 106 (3 µl), and 4 × 106 (5 µl) cells, respectively. Then 
total RNA was isolated from recipient cells and RT-PCR was per-
formed for the CD-UPRT-EGFP and GAPDH mRNAs. As shown 
in Figure 3a, increasing amounts of the CD-UPRT-EGFP mRNA 
were observed in HEI-193 cells exposed to the higher numbers of 
MVs, supporting MV-mediated transfer of mRNA into the recipi-
ent cells. To test whether our delivery system was functional in cul-
ture, we treated HEI-193 cells (105) with CD-UPRT-EGFP mRNA/
protein-enriched MVs (15 µl out of 50 µl MVs collected from 4 × 107 
donor cells) and 2 days later added the prodrug, 5-FC to the medium 
followed by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide) viability assay 24 hours later. We found that HEI-
193 cells treated with MVs carrying the CD-UPRT-EGFP mRNA/
protein showed significant cell death (about 80%), compared with 
cells exposed to the control MVs carrying EGFP mRNA/protein 
after treatment with 5-FC (Figure 3b). In order to evaluate any non-
specific cell toxicity due to aggregated proteins which co-pelleted 
with MVs during MV isolation, we also purified MVs via sucrose 
gradient  ultracentrifugation  (fractions  3–7)34  and  repeated  the 
experiments performed in Figure 3b and observed a pronounced 
and significant cell death (about 40%) in cells treated with these 
sucrose density isolated CD-UPRT-EGFP MVs compared with cells 
exposed to control MVs (prepared in a similar manner) carrying 
EGFP mRNA/protein after treatment with 5-FC (Supplementary 
Figure S1). This supports the tumor toxicity of MVs, but does not 
exclude some portion being contributed by protein aggregates using 
centrifugal pelleting. The ultracentrifugation protocol used for MV 
isolation in Figure 3b yielded MVs which were mostly 100–150 nm 
in diameter (mean 159 nm), but included an additional larger frac-
tion 200–350 nm in diameter, whereas the sucrose gradient protocol 
yielded mostly MVs of a smaller size 50–60 nm in diameter (mean 
104 nm; Supplementary Figure S2). Moreover, ultracentrifugation 
gave ~3–4 times more MVs than that sucrose gradient method from 
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Figure 2  the cd-uPrt-eGFP mrnA and protein are enriched in MVs. (a) Total RNA was isolated from MVs collected from HEK-293T cells trans-
fected with pCD-UPRT-EGFP vector and qRT-PCR was performed for the CD-UPRT and GAPDH mRNAs. The end PCR products were loaded onto 
agarose gel. CD-UPRT mRNAs levels to GAPDH are shown. (b) After MV collection in a, DNase and RNase treatment were performed on MVs and/
or their contents, as indicated. Similar qRT-PCR reactions were performed as in a and the end product DNA was loaded onto agarose gels. A repre-
sentative agarose gel from three independent qRT-PCRs is shown. (c) Nucleic acid content of MVs were treated with DNase or left non-treated and 
then qPCRs were performed directly without RT and PCR products were loaded onto agarose gels. (d) Western blot analysis was carried out on MVs 
(40 µg protein) collected from HEK-293T transfected with pEGFP or pCD-UPRT-EGFP or non-transfected. HEK-293T cell lysates (10 µg) from pCD-
UPRT-EGFP plasmid-transfected cells were used as a positive control for the CD-UPRT-EGFP fusion protein. CD, cytosine deaminase; EGFP, enhanced 
green fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MV, microvesicle; Nt, nucleotide; qPCR, quantitative PCR; qRT-PCR, 
quantitative reverse transcription-PCR; UPRT, uracil phosphoribosyltransferase.104  www.moleculartherapy.org  vol. 21 no. 1 jan. 2013
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the same number of HEK-293T cells. The somewhat decreased cell 
death using sucrose density prepared MVs as compared with pel-
leted MVs observed in Figure 3b may also be a consequence in the 
latter of larger MVs, known to be produced by tumorigenic cells27 
like HEK-293T cells carrying a greater amount per vesicle of the 
EGFP-CD-UPRT mRNA/protein, as well as delivery of more MVs 
per cell. For treatment of tumor cells, the number of MVs per cell 
was the same for MVs isolated by the two methods. Treatment of 
HEI-193 cells with MVs isolated with sucrose gradient method is 
also show in Supplementary Figure S3, which also provided evi-
dence that larger MVs are lost during sucrose gradient preparation 
and produces relatively less MVs.
Treatment of other human cancer cell lines, glioblastoma U87 
and meningioma SF443 with the same concentration of CD-UPRT-
EGFP–loaded  MVs  also  resulted  in  significant  cell  death  after 
prodrug administration in culture (Supplementary Figure S4a,b). 
Transfer of the CD-UPRT-EGFP mRNAs in those cells via MVs was 
confirmed  with  RT-PCR  (Supplementary Figure S4c),  together 
suggesting that this MV-mediated suicide gene therapy approach is 
effective for a number of tumor cell types.
Under  similar  experimental  conditions,  HEI-193  cells  were 
treated for 16 and 24 hours with MVs isolated from HEK-293T 
transfected  with  pCD-UPRT-EGFP  or  pEGFP  and  examined 
by  fluorescence  microscopy  at  indicated  time  points.  In  these 
experimental  conditions,  MVs  were  directly  obtained  from  the 
medium of the transfected cells without any ultracentrifugation. We 
observed increased intracellular EGFP signal over time in MV-CD-
UPRT-EGFP–  and  MV-EGFP–treated  cells  indicating  uptake  of 
MVs by recipient cells with expression of EGFP continuing over 
at least 24 hours, apparently due at least in part to translation of 
the CD-UPRT-EGFP mRNA rather than just MV transfer of this 
protein (Supplementary Figure S5a,b). EGFP signal was observed 
prominently in the cytoplasm of the cells treated with MV-CD-
UPRT-EGFP, whereas MV-EGFP–treated cells exhibited a diffused 
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Figure 4  Intratumoral delivery of MVs carrying the cd-uPrt-eGFP 
mrnA/protein inhibited schwannoma tumor growth in vivo. (a) HEI-
193FC cells were injected (3 × 104 cells in 1 µl of culture medium) into 
the sciatic nerve of nude mice starting 3 weeks after tumor implantation. 
MVs harvested from HEK-293T cells transfected with either pCD-UPRT-
EGFP or pEGFP plasmids were injected weekly into tumors for 2 months 
(using 1 µl per tumor out of 20 µl MVs isolated from 4 × 107 cells) and 
prodrug 5-FC was given daily through intraperitoneal injections following 
the initial MV injection. Tumor growth was monitored by in vivo biolu-
minescence imaging using the Xenogen IVIS system to monitor photon 
emission. Bioluminescent images are shown with a pseudocolor bar to 
indicate degree of bioluminescence at 1, 28, and 56 days after tumor cell 
implantation. (b) The average photon counts of the groups is represented 
as an index of tumor growth, starting with 100% as the initial value. The 
values are expressed as the mean ± SD (***P < 0.001, Student’s t-test). 
5-FC, fluorocytosine; CD, cytosine deaminase; EGFP, enhanced green fluo-
rescent protein; MV, microvesicle; UPRT, uracil phosphoribosyltransferase.
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Figure 3  MVs carrying the cd-uPrt-eGFP mrnA/protein are func-
tional in recipient cells. (a) Three days after treatment of HEI-193 with 
MVs  carrying  CD-UPRT-EGFP  mRNA/protein  in  increasing  concentra-
tions (1, 3, and 5 µl), total RNA was isolated and RT-PCR was performed 
for the CD-UPRT-EGFP and GAPDH mRNAs and products resolved by 
ethidium bromide gel electrophoresis. (b) MTT assays were performed 
on HEI-193 cells 3 days after exposure to MVs containing CD-UPRT-
EGFP mRNA/protein or control EGFP, in both cases with prodrug 5-FC 
treatment. The experiments were performed in triplicate, and the val-
ues are expressed as the mean ± SD (***P < 0.001, Student’s t-test). 
5-FC, 5-fluorocytosine; CD, cytosine deaminase; EGFP, enhanced green 
fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydroge-
nase;  MTT,  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bro-
mide; MV, microvesicle; RT-PCR, reverse transcription-PCR; UPRT, uracil 
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EGFP signal both in nucleus and cytoplasm. Similar localization 
patterns of CD-UPRT-EGFP fusion protein and EGFP alone were 
also  observed  when  they  expressed  from  plasmid  DNAs,  pCD-
UPRT-EGFP or pEGFP (Supplementary Figure S6).
Intratumoral delivery of MVs carrying cd-uPrt-eGFP 
mrnA/protein inhibits schwannoma tumor growth 
in vivo
To test whether this therapeutic MV delivery system was func-
tional in vivo, we used an orthotopic pre-established schwannoma 
tumor model which we recently developed.32,33 HEI-193 cells were 
stably transduced to express firefly luciferase (Fluc) and mCherry 
(mCh), yielding HEI-193FC cells.35 In order to establish tumors, 
3  ×  104  HEI-193FC  cells  in  1 μl  of  medium  were  implanted 
directly into the sciatic nerve of nude mice. Tumor development 
was monitored by in vivo bioluminescence imaging over 3 weeks 
and mice were regrouped so that both groups harbored a range 
of similarly sized tumors based on photon counts. MVs carrying 
CD-UPRT-EGFP mRNAs/protein or EGFP mRNA/protein were 
prepared under similar experimental conditions and resuspended 
in 20 µl. One µl of the MVs were injected into each tumor once 
a week for 2 months, with fresh, loaded MVs prepared for each 
injection. Prodrug, 5-FC was administered intraperitoneally at 
daily intervals (12 mg/day) after the first MV injection. Two inde-
pendent in vivo studies were conducted using a total of 10 mice in 
the control group (EGFP + 5-FC treated) and 9 in the treatment 
group  (CD-UPRT-EGFP  +  5-FC  treated).  Tumor  growth  was 
monitored by in vivo bioluminescence imaging at 28-day intervals. 
Bioluminescence images of tumors in these mice in two indepen-
dent experiments are shown in Figure 4a,b and Supplementary 
Figure  S7a,b  including  quantification  of  the  average  photon 
counts. As shown in Figure 4 and Supplementary Figure S7 in 
the treatment groups (CD-UPRT-EGFP + 5-FC), tumor growth 
was completely inhibited in six of nine mice, whereas all tumors in 
EGFP + 5-FC control mice continued to grow. The lack of regres-
sion of the tumor in three of the treated mice is believed to be 
due to the difficulty in injecting directly into the tumor within the 
sciatic nerve. In control groups, in vivo imaging was terminated at 
day 56 because of excessive size of tumors. In the treatment group, 
in vivo imaging was carried out for an additional 2 weeks beyond 
that and none of the mice developed tumors.
dIscussIon
This study provides the first evidence for the potential therapeu-
tic use of cell-derived MVs as novel and natural gene delivery 
vehicles for cancer treatment. In this strategy the “donor” cells 
are genetically engineered to express high levels of a condition-
ally therapeutic message and protein which are then incorporated 
into MVs derived from these cells. We first transfected HEK-
293T cells with pCD-UPRT-EGFP plasmid and then allowed the 
CD-UPRT mRNA/protein to be incorporated into the MVs for 
3 days followed by isolation and concentration of the MVs by 
ultracentrifugation. We showed that both the CD-UPRT-EGFP 
message and protein were enriched in these MVs and were col-
lectively functional. When recipient tumor cells were exposed to 
these loaded MVs and the prodrug, 5-FC, it was converted to its 
active form leading to cell death. Furthermore, in in vivo studies, 
when  pre-established  mouse  sciatic  nerve  schwannomas  were 
injected intratumorally with CD-UPRT-mRNA/protein-bearing 
MVs and treated with 5-FC, there was marked inhibition of tumor 
growth and regression of tumor size in two independent studies. 
It is likely that this therapeutic effect is mediated by both mRNA 
and protein delivery, but we are not able to evaluate the contribu-
tion of each in the current assays, but together make up a novel 
gene delivery tool: MVs carrying mRNAs/protein. Taken together, 
these data suggest that MVs can be used as a gene delivery tool to 
treat cancer.
Ideal therapeutic delivery vehicles should have a good packag-
ing size and no immunogenic response in the host organism.1 Due 
to the fact that MVs are stable enough to have a relatively long hal-
flife in tissues, small enough to diffuse throughout target tissues, 
and large enough to carry sufficient amounts of genetic and pro-
tein material for different purposes, they may prove to be among 
the most potent biological gene/protein delivery vehicles.1 Since 
therapeutic MVs can be derived from the host own cells placed 
in culture, they have the potential to evade the host’s immune sys-
tem, and with further modifications of membrane components, 
immunogenicity may be further decreased. For example, the host 
cells can be engineered to produce immunosuppressive ligands 
or cytokines which MVs derived from those engineered cells will 
also carry.36 In addition, introduction of specific peptides, such as 
targeting moieties onto the MV membrane should serve to target 
MVs to specific cell populations37 or tissues, such as the brain with 
access across the blood–brain barrier.38 Further, these cell-derived 
“physiologic liposomes” can carry multiple components including 
miRNA, mRNA, non-coding regulatory RNAs, proteins, and DNA 
(for review see ref. 26). Interestingly, we have recently described 
a zipcode-like 25 nt sequence in the 3′UTRs of many of the most 
enriched mRNAs in MVs derived from human primary glioblas-
toma cells, which enhances mRNA incorporation into MVs, in 
part through interaction with miR-1289.39
When  compared  with  current  viral  gene  delivery  tools, 
MVs derived from an individual’s cells should be recognized as 
“self” by the body, resulting in less immune response in the host 
organism to the delivery vehicle, as compared with virus vectors. 
Furthermore, some viral constructs also induce protein kinase R 
stress signaling in host cells.40 Herpes simplex virus also encodes 
proteins, e.g., UL41 (vhs) that block host cell protein translation,41 
and these cellular and viral proteins can be toxic to cells in their 
own right and may interfere with action of therapeutic proteins.42
MVs can be taken up by endocytosis or fusion with the recipi-
ent cell plasma membrane as determined by membrane-bound 
protein  interactions,  after  which  genetic  and  protein  material 
within the MVs are released into the cells. Although protein kinase 
R signaling and many other ribonucleases recognize foreign bacte-
rial or viral RNA/DNA molecules, MVs mRNA molecules should 
have the common eukaryotic signals, such as untranslated regions 
at the 5′ and 3′ terminals, capping at the 5′ terminal, and coding 
sequences, which are distinct from microbial mRNAs. In addition, 
the immune system should recognize MVs produced by normal 
cells as self due to immunologic memory as these MVs are pres-
ent in all body fluids, including blood and urine.43,44 Several stud-
ies also support the functional nature of transferred miRNAs and 
mRNAs which modify the translational profile and phenotype of 106  www.moleculartherapy.org  vol. 21 no. 1 jan. 2013
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the recipient cells.22,23,38,45–48 A recent study also showed that MVs 
derived from genetically engineered dendritic cells can success-
fully transfer siRNA molecules to mouse brain with consequent 
downregulated translation of targeted mRNAs.38
Taken together–less immunogenic response, abundant gene/
protein transfer capacity, and ample packaging size, cell-derived 
MVs have immense potential as therapeutic delivery vehicles for 
disease applications in the future. Two applications can be envi-
sioned. In one strategy, cells from the affected individual would 
be placed in culture, genetically modified as needed for target-
ing and delivery of the therapeutic protein/RNA and then MVs 
isolated from cultures administered to the patient, as modeled in 
Alvarez-Erviti et al.38 In the context of cancer therapy, it will be 
important that the therapeutic gene does not kill the donor cells, 
so, for example, it could be a prodrug-activating enzyme, as in this 
study, or a protein such as a membrane-bound form of TRAIL 
which is not toxic to most normal cells, but kills tumor cells upon 
transfer.49 In a second strategy, it should be possible to genetically 
modify cells in vivo so that they produce conditionally therapeutic 
MVs, such as the prodrug-activating scheme used in this study 
to empower tumor cells so that they “become their own worst 
enemies”. The results presented here provide a proof-of-concept 
that MVs can serve as therapeutic delivery vehicles for cancer and 
other diseases.
MAterIAls And Methods
Plasmids. Yeast CD – yeast UPRT ORF (pORF-FcyFur; Invitrogen, Grand 
Island, NY) was fused to the N terminus of EGFP in pEGFP-N1 plasmid 
(Clontech, Mountain View, CA) under the cytomegalovirus promoter and 
the plasmid construct is referred to as pCD-UPRT-EGFP in these studies. 
Forward 5′-GCTTCGAATTCATGGTCACAGGAGGCATGGCTTC and 
reverse  5′-GACCGGTGGATCCACACAGTAGTATCTGTCCC  primers 
were used to amplify CD:UPRT by conventional PCR with Pfu Polymerase 
(Stratagene, Santa Clara, CA) in cloning steps.
Cells.  HEK-293T  cells  (from  Dr  Maria  Calos,  Stanford  University, 
Stanford,  CA)  were  cultured  in  Dulbecco’s  Modified  Eagle  Medium 
(DMEM; Cellgro, Mediatech, Manassas, VA) containing 10% fetal bovine 
serum (FBS). Human schwannoma cell line HEI-193 established from a 
schwannoma tumor from a NF2 patient and immortalized with retrovi-
ral-mediated HPV E6-E7 transduction (from Dr David Lim, House Ear 
Institute, Los Angeles, CA) was cultured, as described.31 These cells were 
transduced with a lentivirus vector expressing Fluc and mCh, termed HEI-
193FC cells, as described.35 Meningioma cells, SF443 (from Dr Anita Lal, 
University of California, San Francisco, CA) were cultured, as described 
previously.50,51 U87 cells (ATCC, Manassas, VA) were cultured in DMEM 
containing 10% FBS. All cells were grown in the presence of 100 IU/ml 
penicillin and 100 µg/ml streptomycin and incubated at 37 °C in a 5% CO2 
atmosphere. Cells were determined to be mycoplasma negative by test-
ing with a mycoplasma detection kit (MycoAlert Mycoplasma Detection 
Assay; Lonza, Rockland, ME).
MVs isolation. HEK-293T cells (maintained within 10 passages) were trans-
fected either with pEGFP-N1 or pCD-UPRT-EGFP using Lipofectamine 
2000 (Invitrogen), according to manufacturer’s protocol. Five hours later, 
transfection media was replaced with media containing 5% MV-free FBS.22 
Three days after transfection, MVs were harvested, as described.22 Briefly, 
culture medium from 2 × 150 mm plates containing 2 × 107 cells per plate 
was first centrifuged at 300g for 15 minutes to separate cells from medium, 
then at 16,000g for 30 minutes to precipitate cellular debris. The superna-
tants were filtered through 0.22 µm filters (Millex, Billerica, MA) and then 
a final ultracentrifugation was performed at 110,000g for 80 minutes using 
Beckman Quick seal tubes and a 70Ti rotor (Beckman Coulter, Fullerton, 
CA). Pelleted MVs were eluted either in 50 µl (for in vitro experiments) or 
20 µl (for in vivo studies) in a mixture containing 1× phosphate-buffered 
saline, RNase inhibitor (2 µl, 10U-RNAse-OUT—Invitrogen) and rDNase I 
(1 µl, 2U-DNA-free—Ambion, Grand Island, NY). One µl MVs were deliv-
ered into each tumor once a week for 2 months, with fresh MVs prepared 
for each injection. Every 2 weeks, we generated new, early passage cultures 
of the cells to isolate MVs to make sure that there were no extended passage 
differences between the cells from which the MVs were isolated. MV yields 
were determined by measuring total RNA content using a NanoDrop 1000 
(NanoDrop, Wilmington, DE) which correlated directly with MV number 
as assessed using a Nanosight, NS500 (Supplementary Figure S8).
For in vivo studies, MVs were prepared in the same manner and 
similar amounts of MVs were used in both groups as assessed by total 
RNA content: 189 ± 21 ngin 20 µl for CD-UPRT-EGFP MVs and 201 ± 
38 ng in 20 µl for the control EGFP MVs. In some cases MVs were treated 
with 1 µl DNaseI (2U; Ambion) in 50 µl of total reaction for 30 minutes at 
37 °C to remove DNA bound to the surface. In order to make sure that our 
DNase treatment protocol was functional, we performed qPCR reactions 
in the absence of RT directly from the MVs content and found no PCR 
amplification suggesting that the treatment protocol completely removed 
any plasmid DNA purified during MVs isolation.
Sucrose gradient ultracentrifugation. Sucrose gradient ultracentrifuga-
tion was performed, as described previously.34 Briefly, MVs were layered 
onto a sucrose density gradient (8, 30, 45, 60% layers) and centrifuged for 
38 minutes at 50,000 rpm in SW40Ti swinging bucket rotor (Beckman 
Coulter) in a Beckman Optima ultracentrifuge with deceleration set to 
slow. Fractions 3–7 (density: fraction 3 contains: half 8%, half 30%, frac-
tions 4 and 5 contains 30% only, fractions 6 and 7 contains 45% only) 
were collected, diluted in phosphate-buffered saline and MVs pelleted at 
100,000g for 75 minutes in the S50A rotor using a Sorvall MX-120 micro-
centrifuge (Thermo Fisher Scientific, Agawam, MA) and used for western 
blot analysis for MV-associated proteins.
Total  RNA  isolation,  reverse  transcription,  and  qPCR.  RNA  was  iso-
lated from MVs using the miRvana kit (Ambion), according to manu-
facturer’s  protocol.  Reverse  transcription  reaction  was  performed  with   
150 ng of MV RNA using Omniscript (Qiagen, Valencia, CA). Relative 
mRNA  amounts  were  quantified  with  Applied  Biosystems  7000  series   
qPCR  using  SYBR  Green  (Applied  Biosystems,  Grand  Island,  NY).   
Forward 5′-CACAACATGAGGTTCCAGAA and reverse 5′-GAAGTTGA 
CATTCTCTCCCA  primers  were  used  to  detect  CD-UPRT-GFP  mes-
sage and forward 5′-GAAGGTGAAGGTCGGAGT and reverse 5′-GAA 
GATGGTGATGGGATTTC  primers  for  GAPDH  mRNA.  Threshold   
cycles  (CT)  were  analyzed  using  the  Δ-CT  formula  and  normalized 
to  GAPDH  mRNA  levels.  The  quantitive  RT-PCR  analysis  was  based 
on  threshold  cycles  of  the  non-transfected  cells-derived  MVs  and  the 
CD-UPRT-GFP transfected cell-derived MVs. The fold enrichment was cal-
culated by comparing CT values. The highest CT value of qPCR (CT = 30),   
indicating non-detectable levels of mRNA, was taken as our reference point 
in non-transfected and control plasmid, pEGFP, transfected cells and nor-
malized to GAPDH CT values. Although the non-transfected cells-derived 
MVs did not have the CD-UPRT-GFP message, the Δ-CT value of the 
non-transfected cells-derived MV samples were considered as 1 (CT = 30)   
in order to determine the minimal level of enrichment of CD message in 
CD-UPRT-MVs.
Western blot analysis. MVs were collected as described above and total 
protein  (40 µg/lane)  was  resolved  by  electrophoresis  in  SDS–8%  poly-
acrylamide gels and blotted onto nitrocellulose membranes, as described 
previously.51 The primary antibodies used were CD (#4012; Cell Signaling 
Technology,  Danvers,  MA)  at  1:1,000  dilution,  and  β-actin  (#A5441; 
Sigma-Aldrich, St Louis, MO) at 1:1,000 dilution. Goat-anti-mouse IgG Molecular Therapy  vol. 21 no. 1 jan. 2013  107
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HRP conjugated (DAKO, Glostrup, Denmark; 1:5,000, cat. no. P0447) was 
used as a secondary antibody.
Cell viability assay. HEI-193 cells were seeded (5,000 per well) into 96-well 
plates 1 day before MV introduction. MVs were harvested from HEK-293 
cells and eluted in 50 µl of cocktail mix (see above) and 15 µl was added into 
the medium in each well. Cells were incubated with MVs for 2 days before 
prodrug treatment and then treated with 250 µg/ml 5-FC (cat. no. sud-5fc; 
Invitrogen). Three days later, MTT (Invitrogen) assays were performed, 
according to manufacturer’s protocol to quantify cell viability.
Schwannoma  tumor  development  and  bioluminescence  imaging. 
Schwannoma tumors were developed as described previously.32,33 Briefly, 
HEI-193FC cells were trypsinized and rinsed, and then 3 × 104 cells in 1 µl 
culture medium were injected directly into the sciatic nerve of athymic 
mice (nu/nu, 5-week-old females; Cox 7 breeding facility, Massachusetts 
General Hospital, Boston, MA). In vivo bioluminescence imaging was per-
formed, as described previously.32,33
suPPleMentArY MAterIAl
Figure S1.  Effect of MV-CD-UPRT-EGFP and MV-EGFP on cell viability 
after purification by sucrose gradient ultracentrifugation.
Figure S2.  MVs size comparison by NanoSight.
Figure S3.  MVs uptake of HEI-193 cells after purification by sucrose 
gradient ultracentrifugation.
Figure S4.  Genetically engineered MVs kill other cancer cell types.
Figure S5.  CD-UPRT-EGFP expression increases in recipient cells over 
time.
Figure S6.  pCD-UPRT-EGFP and pEGFP expression patterns in plas-
mid DNA transfected HEK-293T cells.
Figure S7.  Inhibition  of  schwannoma  tumor  growth  after  intratu-
moral delivery of MVs carrying the CD-UPRT-EGFP mRNA/protein.
Figure S8.  Correlation between MVs numbers and RNA content.
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